Micro Cap Growth Fund
Daily price w/o sales charge as of 12/12/2024
$18.19
$0.26
YTD Returns w/o sales charge as of 12/12/2024
31.15%
Please click here for performance current to the most recent quarter-end and month-end.
Summary
Summary
Fund Basicsas of 11/29/2024
- Total Net Assets
- $217.44 M
- Inception Date
- 05/01/2000
- Dividend Frequency
- Annually
- Fund Gross Expense Ratio
- 1.37%
- Fund Net Expense Ratio
- 1.37%
- Number of Holdings
- 62
- Minimum Initial Investment
- $1,500+
Fund Expense Ratio :
Gross 1.37%
Net 1.37%
| YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 05/01/2000 |
|---|
| w/o sales charge | 33.53% | 47.10% | 0.38% | 14.33% | 13.70% | 10.54% |
| Lipper Category Avg. Small-Cap Growth Funds | 23.95% | 36.36% | 1.71% | 10.08% | 10.17% | - |
| Russell Microcap® Growth Index | 27.37% | 44.79% | -1.66% | 8.06% | 6.36% | - |
| w/ sales charge | 25.82% | 38.62% | -1.59% | 12.98% | 13.02% | 10.27% |
Fund Expense Ratio :
Gross 1.37%
Net 1.37%
Fund Expense Ratio :
Gross 1.37%
Net 1.37%
| YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 05/01/2000 |
|---|
| w/o sales charge | 15.14% | 28.07% | -4.23% | 13.67% | 13.16% | 9.94% |
| Lipper Category Avg. Small-Cap Growth Funds | 13.34% | 26.11% | -1.27% | 9.68% | 9.84% | - |
| Russell Microcap® Growth Index | 9.29% | 26.38% | -8.31% | 6.86% | 5.42% | - |
| w/ sales charge | 8.49% | 20.71% | -6.10% | 12.33% | 12.49% | 9.68% |
Fund Expense Ratio :
Gross 1.37%
Net 1.37%
Returns with sales charges reflect a maximum sales charge of 5.75%.
The performance quoted represents past performance, which is no indication of future results. Current performance may be higher or lower than the performance data quoted. Returns shown include the reinvestment of all distributions. Returns shown at net asset value do not reflect the current maximum sales charge, had the sales charge been included, returns would have been lower. The investment return and principal value of an investment will fluctuate so that shares, on any given day or when redeemed, may be worth more or less than the original cost. Therefore, there can be no assurance for future results.
TEN LARGEST HOLDINGS as of 10/31/2024View Portfolio
| Holding | Assets |
|---|---|
| Tarsus Pharmaceuticals Inc | 3.2% |
| VSE Corp | 2.7% |
| Zeta Global Holdings Corp | 2.6% |
| Alkami Technology Inc | 2.6% |
| PROCEPT BioRobotics Corp | 2.5% |
| Vital Farms Inc | 2.3% |
| Sweetgreen Inc | 2.3% |
| Arcellx Inc | 2.2% |
| Willdan Group Inc | 2.2% |
| GeneDx Holdings Corp | 2.2% |
Aggregate holdings are updated monthly, 30 days after month end. Aggregate holdings are presented to illustrate examples of the securities that the Fund has bought and the diversity of the areas in which the Fund may invest, and may not be representative of the Fund's current or future investments. The figures presented are as of the date shown and may change at any time.
Sector Allocationas of 11/29/2024View Portfolio
| Sector | Weighting |
|---|
| Sector | Weighting |
|---|---|
| Communication Services | |
| Other | |
| Real Estate | |
| Utilities | |
| Consumer Discretionary | |
| Consumer Staples | |
| Energy | |
| Financials | |
| Health Care | |
| Industrials | |
| Information Technology | |
| Materials |
INVESTMENT TEAM
Your Representative
To contact your representative, enter your zip code and select your channel below.
Performance
Performance
Fund Expense Ratio :
Gross 1.37%
Net 1.37%
| YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 05/01/2000 |
|---|
| w/o sales charge | 33.53% | 47.10% | 0.38% | 14.33% | 13.70% | 10.54% |
| Lipper Category Avg. Small-Cap Growth Funds | 23.95% | 36.36% | 1.71% | 10.08% | 10.17% | - |
| Russell Microcap® Growth Index | 27.37% | 44.79% | -1.66% | 8.06% | 6.36% | - |
| w/ sales charge | 25.82% | 38.62% | -1.59% | 12.98% | 13.02% | 10.27% |
Fund Expense Ratio :
Gross 1.37%
Net 1.37%
Fund Expense Ratio :
Gross 1.37%
Net 1.37%
| YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 05/01/2000 |
|---|
| w/o sales charge | 15.14% | 28.07% | -4.23% | 13.67% | 13.16% | 9.94% |
| Lipper Category Avg. Small-Cap Growth Funds | 13.34% | 26.11% | -1.27% | 9.68% | 9.84% | - |
| Russell Microcap® Growth Index | 9.29% | 26.38% | -8.31% | 6.86% | 5.42% | - |
| w/ sales charge | 8.49% | 20.71% | -6.10% | 12.33% | 12.49% | 9.68% |
Fund Expense Ratio :
Gross 1.37%
Net 1.37%
Returns with sales charges reflect a maximum sales charge of 5.75%.
The performance quoted represents past performance, which is no indication of future results. Current performance may be higher or lower than the performance data quoted. Returns shown include the reinvestment of all distributions. Returns shown at net asset value do not reflect the current maximum sales charge, had the sales charge been included, returns would have been lower. The investment return and principal value of an investment will fluctuate so that shares, on any given day or when redeemed, may be worth more or less than the original cost. Therefore, there can be no assurance for future results.
| Year | Fund Returns | Russell Microcap® Growth Index |
|---|
| 2023 | 5.88% | 9.11% |
| 2022 | -29.27% | -29.76% |
| 2021 | 3.46% | 0.88% |
| 2020 | 79.42% | 40.13% |
| 2019 | 34.57% | 23.33% |
| 2018 | 2.74% | -14.18% |
| 2017 | 38.43% | 16.65% |
| 2016 | 2.07% | 6.86% |
| 2015 | -6.38% | -3.85% |
| 2014 | 10.83% | 4.30% |
| 2013 | 78.53% | - |
| 2012 | 2.35% | - |
| 2011 | -5.87% | - |
| 2010 | 33.77% | - |
| 2009 | 52.61% | - |
| 2008 | -46.45% | - |
| 2007 | 22.76% | - |
| 2006 | 25.37% | - |
| 2005 | 2.55% | - |
| 2004 | 25.89% | - |
| Year | Q1 | Q2 | Q3 | Q4 |
|---|
| 2024 | 7.64% | 0.07% | 6.89% | - |
| 2023 | 5.50% | 4.20% | -13.40% | 11.23% |
| 2022 | -17.22% | -22.57% | 8.17% | 2.02% |
| 2021 | 12.29% | -0.15% | -9.42% | 1.87% |
| 2020 | -24.28% | 47.61% | 17.48% | 36.65% |
| 2019 | 22.67% | 7.47% | -13.91% | 18.57% |
| 2018 | 5.24% | 15.77% | 10.08% | -23.39% |
| 2017 | 9.00% | 8.12% | 13.61% | 3.39% |
| 2016 | -13.70% | 6.01% | 14.49% | -2.55% |
| 2015 | 7.33% | 4.15% | -16.30% | 0.06% |
| 2014 | 7.92% | -6.53% | -6.55% | 17.58% |
| 2013 | 21.83% | 15.00% | 17.29% | 8.65% |
| 2012 | 17.67% | -9.76% | 1.32% | -4.87% |
| 2011 | 4.82% | 0.11% | -21.90% | 14.86% |
| 2010 | 6.60% | -8.74% | 15.08% | 19.49% |
| 2009 | -0.95% | 31.46% | 13.47% | 3.29% |
| 2008 | -23.22% | 4.46% | -5.93% | -29.02% |
| 2007 | 5.64% | 9.81% | 4.01% | 1.76% |
| 2006 | 17.15% | -9.83% | 1.22% | 17.25% |
| 2005 | -9.50% | 5.88% | 6.91% | 0.10% |
| 2004 | 12.33% | 1.65% | -11.11% | 24.03% |
| 2003 | -3.55% | 27.29% | 11.68% | 8.93% |
| 2002 | -0.18% | -12.74% | -21.79% | 1.33% |
| 2001 | 2.34% | 12.03% | -21.11% | 29.32% |
Performance is shown for each quarter and each calendar year. Past performance is no guarantee of future results.
Growth of $10,000 as of 11/30/2024
The chart begins on the Fund's inception date of 05/01/2000.
Based on a hypothetical Class A share investment of $10,000 on 05/01/2000 without sales charge and includes the reinvestment of all distributions.
NAV Historical Prices
| Date | Net Asset Value |
|---|
Portfolio
Portfolio
| Holding | Sector | Assets |
|---|
| Tarsus Pharmaceuticals Inc | Health Care | 3.2% |
| VSE Corp | Industrials | 2.7% |
| Zeta Global Holdings Corp | Information Technology | 2.6% |
| Alkami Technology Inc | Information Technology | 2.6% |
| PROCEPT BioRobotics Corp | Health Care | 2.5% |
| Vital Farms Inc | Consumer Staples | 2.3% |
| Sweetgreen Inc | Consumer Discretionary | 2.3% |
| Arcellx Inc | Health Care | 2.2% |
| Willdan Group Inc | Industrials | 2.2% |
| GeneDx Holdings Corp | Health Care | 2.2% |
Aggregate holdings are updated monthly, 30 days after month end. Aggregate holdings are presented to illustrate examples of the securities that the Fund has bought and the diversity of the areas in which the Fund may invest, and may not be representative of the Fund's current or future investments. The figures presented are as of the date shown and may change at any time.
| Holding | Sector | Assets |
|---|
| Tarsus Pharmaceuticals Inc | Health Care | 3.2% |
| VSE Corp | Industrials | 2.7% |
| Zeta Global Holdings Corp | Information Technology | 2.6% |
| Alkami Technology Inc | Information Technology | 2.6% |
| PROCEPT BioRobotics Corp | Health Care | 2.5% |
| Vital Farms Inc | Consumer Staples | 2.3% |
| Sweetgreen Inc | Consumer Discretionary | 2.3% |
| Arcellx Inc | Health Care | 2.2% |
| Willdan Group Inc | Industrials | 2.2% |
| GeneDx Holdings Corp | Health Care | 2.2% |
| Green Brick Partners Inc | Consumer Discretionary | 2.1% |
| Cellebrite DI Ltd | Information Technology | 2.1% |
| Primoris Services Corp | Industrials | 2.0% |
| Vera Therapeutics Inc | Health Care | 2.0% |
| Agilysys Inc | Information Technology | 2.0% |
| Evolus Inc | Health Care | 2.0% |
| Chefs' Warehouse Inc/The | Consumer Staples | 1.9% |
| Kratos Defense & Security Solutions Inc | Industrials | 1.9% |
| OSI Systems Inc | Information Technology | 1.8% |
| Janux Therapeutics Inc | Health Care | 1.7% |
| CRA International Inc | Industrials | 1.7% |
| Paymentus Holdings Inc | Financials | 1.7% |
| Weave Communications Inc | Information Technology | 1.7% |
| Mirum Pharmaceuticals Inc | Health Care | 1.7% |
| Vita Coco Co Inc/The | Consumer Staples | 1.7% |
| Scholar Rock Holding Corp | Health Care | 1.7% |
| Life360 Inc | Information Technology | 1.6% |
| OneSpaWorld Holdings Ltd | Consumer Discretionary | 1.6% |
| RxSight Inc | Health Care | 1.6% |
| Universal Technical Institute Inc | Consumer Discretionary | 1.5% |
| UFP Technologies Inc | Health Care | 1.5% |
| Natural Grocers by Vitamin Cottage Inc | Consumer Staples | 1.5% |
| Grid Dynamics Holdings Inc | Information Technology | 1.5% |
| Credo Technology Group Holding Ltd | Information Technology | 1.4% |
| Stride Inc | Consumer Discretionary | 1.4% |
| Piper Sandler Cos | Financials | 1.4% |
| Grindr Inc | Communication Services | 1.4% |
| Nurix Therapeutics Inc | Health Care | 1.3% |
| Enliven Therapeutics Inc | Health Care | 1.3% |
| Payoneer Global Inc | Financials | 1.3% |
| Argan Inc | Industrials | 1.3% |
| Impinj Inc | Information Technology | 1.3% |
| Xenon Pharmaceuticals Inc | Health Care | 1.3% |
| Core Scientific Inc | Information Technology | 1.3% |
| Viridian Therapeutics Inc | Health Care | 1.2% |
| Crinetics Pharmaceuticals Inc | Health Care | 1.2% |
| Sterling Infrastructure Inc | Industrials | 1.2% |
| Sapiens International Corp NV | Information Technology | 1.2% |
| Veracyte Inc | Health Care | 1.1% |
| ICF International Inc | Industrials | 1.1% |
| IMAX Corp | Communication Services | 1.1% |
| Artivion Inc | Health Care | 1.0% |
| Centessa Pharmaceuticals PLC | Health Care | 1.0% |
| TWFG Inc | Financials | 1.0% |
| Ceribell Inc | Health Care | 1.0% |
| Rhythm Pharmaceuticals Inc | Health Care | 1.0% |
| Blue Bird Corp | Industrials | 0.9% |
| Avid Bioservices Inc | Health Care | 0.9% |
| Criteo SA | Communication Services | 0.9% |
| Bancorp Inc/The | Financials | 0.9% |
| Warby Parker Inc | Consumer Discretionary | 0.7% |
| CareDx Inc | Health Care | 0.7% |
| Twist Bioscience Corp | Health Care | 0.5% |
| Ambarella Inc | Information Technology | 0.5% |
Aggregate holdings are updated monthly, 30 days after month end. Aggregate holdings are presented to illustrate examples of the securities that the Fund has bought and the diversity of the areas in which the Fund may invest, and may not be representative of the Fund's current or future investments. The figures presented are as of the date shown and may change at any time.
Sector Allocationas of 11/29/2024
| Sector | Weighting | Fund Change from Previous Quarter |
|---|
| Sector | Weighting | Fund Change from Previous Quarter |
|---|---|---|
| Communication Services |
0.4%
|
|
| Other | 0.0% | |
| Real Estate | 0.0% | |
| Utilities | 0.0% | |
| Consumer Discretionary |
 0.1%
|
|
| Consumer Staples |
0.2%
|
|
| Energy | 0.0% | |
| Financials |
2.3%
|
|
| Health Care |
0.1%
|
|
| Industrials |
1.9%
|
|
| Information Technology |
1.7%
|
|
| Materials |
1.3%
|
Portfolio Details as of 11/29/2024
- Total Net Assets
- $217.44 M
- Number of Holdings
- 62
- Weighted Average Market Cap.
- 3.0 B
- P/B Ratio
- 6.1x
- P/E Ratio
- 35.9x
To view definitions for the above Portfolio Details, Click here.
P/B Ratio - A ratio that helps determine whether a stock is undervalued or overvalued. It is calculated by dividing a stock's price per share by its book value per share. The result is based upon a weighted average of the securities held in the fund.
P/E Ratio - Is the weighted average of each holding's P/E ratio (price of a stock divided by its earnings per share). The result is based upon a weighted average of the securities held in the fund.
Weighted Average Market Cap - The average market capitalization of all companies held in the portfolio with each company weighted according to its percent held in the portfolio. The result is based upon a weighted average of the securities held in the fund.
Dividends & Cap Gains
Dividends & Cap Gains
Dividend Payments
- YTD Dividends Paidas of 12/12/2024
- $0
- Dividend Frequency
- Annually
| Record Date | Ex-Dividend Date | Reinvest & Payable Date | Dividend | Reinvest Price |
|---|---|---|---|---|
| 11/20/2001 | 11/21/2001 | 11/21/2001 | $0.00740 | $10.09 |
Capital Gains Distributions
| Record Date | Reinvest & Payable Date | Long-term | Short-term * | Total | Reinvest Price |
|---|---|---|---|---|---|
| 11/23/2020 | 11/24/2020 | $2.8043 | $2.2741 | $5.0784 | $15.43 |
Taxed as ordinary income
Lord Abbett does not provide tax advice. It is strongly recommended that you discuss the impact of dividends and distributions with your tax advisor.
Fees & Expenses
Fees & Expenses
Sales Charge Schedule as of 12/12/2024
| Sales Charge | Dealer's Concession | Prices at Breakpoint | |
|---|---|---|---|
| Less than $50,000 | 5.75% | 5.00% | $19.30 |
| $50,000 to $99,999 | 4.75% | 4.00% | $19.10 |
| $100,000 to $249,999 | 3.95% | 3.25% | $18.94 |
| $250,000 to $499,999 | 2.75% | 2.25% | $18.70 |
| $500,000 to $999,999 | 1.95% | 1.75% | $18.55 |
| $1,000,000 to $5,000,000 | 0.00% | 1.00% | $18.19 |
The 12b-1 trail commission is 0.15% (accrues immediately) for all fixed-income and municipal income funds.
Class A shares purchased without a sales charge (commissionable NAV) will be subject to a CDSC of 1% if they are redeemed before the first day of the month in which the one-year anniversary of the purchase falls.
Expense Ratioas of 11/30/2024
| Fund Gross Expense Ratio | 1.37% |
| Fund Net Expense Ratio | 1.37% |
Fund Documents
Fund Documents
|
0Documents selected
|
||||
|---|---|---|---|---|
|
Portfolio Holdings 1Q
Publish Date:11/03/2015
|
||||
|
Portfolio Holdings 3Q
Publish Date:11/03/2015
|
||||
|
Summary Prospectus
Publish Date:11/03/2015
|
||||
|
Statutory Prospectus
Publish Date:11/03/2015
|
||||
|
SAI
Publish Date:11/03/2015
|
||||
|
Annual Financial Statements and Other Information *
Publish Date:11/03/2015
|
||||
|
Semi-Annual Financial Statements and Other Information *
Publish Date:11/03/2015
|
||||
|
Fact Sheet
Publish Date:11/03/2015
|